Name (Synonyms) | Correlation | |
---|---|---|
drug2998 | Ultimaster Tansei 80 Micron Wiki | 1.00 |
Name (Synonyms) | Correlation | |
---|---|---|
D006470 | Hemorrhage NIH | 0.50 |
D006331 | Heart Diseases NIH | 0.35 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
The study compares the outcome of the ultrathin stent strut Supraflex Cruz stent to the thin stent strut Ultimaster Tansei stent in a PCI population at high risk for bleeding (HBR).
Description: The primary endpoint Net Adverse Clinical Endpoints (NACE) defined as a composite of cardiovascular death, myocardial infarction, target vessel revascularization, stroke and bleeding events defined as BARC 3 or 5 at 12 months follow-up after the index PCI.
Measure: Net Adverse Clinical Endpoints (NACE) Time: 1 yearDescription: Major adverse cardiac and cerebral events (MACCE) defined as a composite of cardiac death, myocardial infarction, target vessel revascularization and stroke
Measure: Major adverse cardiac and cerebral events (MACCE) Time: 1 yearDescription: Major or clinically relevant non-major bleeding (MCB) defined as a composite of type 2, 3 and 5 BARC bleeding events
Measure: Major or clinically relevant non-major bleeding (MCB) Time: 1 yearDescription: Target Lesion Failure (TLF) is defined as cardiac death, myocardial infarction attributed to the target vessel and clinically indicated target lesion revascularization
Measure: Target Lesion Failure (TLF) Time: 1 yearDescription: Target Vessel Failure (TVF) is defined as cardiac death, myocardial infarction attributed to the target vessel and clinically indicated target vessel revascularization
Measure: Target vessel failure (TVF) Time: 1 yearDescription: The composite endpoint of cardiovascular death, myocardial infarction and stroke
Measure: The composite of cardiovascular death, myocardial infarction and stroke Time: 1 yearDescription: The composite of cardiovascular death, myocardial infarction, stroke and major bleed according to BARC 3 and 5
Measure: The composite of cardiovascular death, myocardial infarction, stroke and major bleed BARC 3 and 5 Time: 1 yearDescription: Stent thrombosis according to the ARC definitions
Measure: Stent thrombosis Time: 1 yearDescription: Myocardial infarction.
Measure: Myocardial infarction Time: 1 yearDescription: Urgent target vessel revascularization.
Measure: Urgent target vessel revascularization Time: 1 yearDescription: Non-target vessel revascularization.
Measure: Non-target vessel revascularization Time: 1 yearDescription: Clinically indicated target vessel revascularization.
Measure: Clinically indicated target vessel revascularization Time: 1 yearDescription: Bleeding events
Measure: Bleeding events Time: 1 yearDescription: Transfusion rates both in patients with and/or without clinically detected over bleeding
Measure: Transfusion rates Time: 1 yearDescription: Event rates according to the PRECISE-DAPT score
Measure: Event rates according to the PRECISE-DAPT Time: 1 yearDescription: Procedural success.
Measure: Procedural success Time: 1 yearDescription: Device success.
Measure: Device success Time: 1 year